Latest News on JBIO

Financial News Based On Company


Advertisement
Advertisement

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - Inhibikase Therapeutics ( NASDAQ:IKT )

https://www.benzinga.com/pressreleases/25/08/g47205503/inhibikase-therapeutics-strengthens-leadership-team-with-appointment-of-timothy-pigot-as-chief-com
BOSTON and ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc.

Jade Biosciences Posts Wider Loss in Q2

https://www.fool.com/data-news/2025/08/13/jade-biosciences-posts-wider-loss-in-q2/
Jade Biosciences ( NASDAQ:JBIO ) , a biotechnology company focused on autoimmune disease therapies, published its results on August 13, 2025. The standout message: the company reported a GAAP net loss that was deeper than expected, with earnings per share ( EPS ) at $ ( 0.61 ) ( GAAP ) , compared ...
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion